Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Clinical trial NCT02625623 · COMPLETED

Trial details

NCT number: NCT02625623
Sponsor: EMD Serono Research & Development Institute, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Gastric Cancer Third Line

Start date: 2015-12-28
Primary completion: 2017-09-14
Enrollment: 371

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.